Stay updated on AVI-7100 Flu Drug Clinical Trial
Sign up to get notified when there's something new on the AVI-7100 Flu Drug Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FvQ2QtKZdWOhd3HuQblP-tOlRsBE.uncropped.jpg&w=3840&q=75)
Latest updates to the AVI-7100 Flu Drug Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0, replacing the previous version v2.9.7.SummaryDifference0.4%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7, replacing the previous version v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the content on the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the web page.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Show more Revision: v2.9.0' has been updated to 'Show less Show less MedlinePlus related topics: Flu FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Single Group Assignment Arms and Interventions Intervention/Treatment Drug : AVI-7100 versus placebo dose-escalating AVI-7100 versus placebo Primary Outcome Measures Outcome Measure Measure Description Time Frame To evaluate the safety and tolerability of AVI-7100 in healthy adults, following single- or multiple-dose, intravenous administration at escalating dose-levels 2 years Secondary Outcome Measures Outcome Measure Measure Description Time Frame To evaluate the pharmacokinetics of intravenously administered AVI-7100 in healthy adults, following single- or multiple-dose, intravenous administration at escalating dose-levels 2 years Keywords Provided by National Institutes of Health Clinical Center (CC) (National Institute of Allergy and Infectious Diseases (NIAID)) Antisense Influenza IV Injection RNA Based Therapeutic RNA Interference Additional Relevant MeSH Terms Respiratory Tract Infections Infections Orthomyxoviridae Infections RNA Virus Infections Virus Diseases Respiratory Tract Diseases Influenza, Human Antiviral Agents Anti-Infective Agents Radavirsen Helpful Links Provided by National Institutes of Health Clinical Center (CC) (National Institute of Allergy and Infectious Diseases (NIAID)) NIH Clinical Center Detailed Web Page Revision: v2.9.1'. This change reflects an update in the detailed information about the clinical trial involving AVI-7100, including safety evaluation, pharmacokinetics, and relevant keywords.SummaryDifference9%
Stay in the know with updates to AVI-7100 Flu Drug Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AVI-7100 Flu Drug Clinical Trial page.